| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.5 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.043 | 0.5 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.6 |